glp-1 cardiovascular outcomes 2025 news Bridging the gap between GLP1-receptor agonists and outcomes: evidence for the role of tirzepatide | Cardiovascular Diabetology glp-1 cardiovascular outcomes 2025 news

In the STEP 5 study, participants taking semaglutide lost an average of 15.2% of their body weight over two years, compared with 2.6% in the placebo group

NA supplementation increased NAD + levels and metabolites in muscle, inducing mitochondrial biogenesis and Oxphos activity, and improved shoulder and knee extension strength

This is where having provider support makes all the difference

Effect of glucagon-like peptide 1 receptor agonists on albuminuria in adult patients with type 2 diabetes mellitus: a systematic review and meta-analysis

Because of this, both drugs are expected to work in the same way for weight loss